Advice on How to Think About a System 'Heading Over a Cliff'

Plus data and insights on "Jan. 1" price changes, thinking on "smoothing", small PBMs in 2025, and more

This Year, Jan. 1 Price Drops Might Be as Interesting as the Price Hikes

Plus some of the 2025 advice you all have sent along (the survey is still live, too!)

'Advice for 2025' Survey Now Live

I Want Your Thoughts: What 2025 Advice Do You Have for Curve Readers?

It's a slow day, but I still managed to find at least one 340B link, because I want to stay on-brand

It's NYE, Which Means Champagne ... and Low-Context Articles About Jan. 1 Drug Price Hikes

But I have some suggestions for reporters looking for a way to stay busy this week without chasing the same, tired price-increase story

A New Lawsuit Crystallizes the Abuses and Lack of Oversight in 340B

And thank you, President Carter, for teaching us all how much global public health matters

CMS' Explanations for 'Maximum Fair Prices' Feel a Bit Like Coal in the Stocking

Have a great holiday, everyone!

Pre-Holiday Wrap: A Couple New Drugs, Some Health Policy Chatter, and More Analyses Putting MFPs in Context

And thanks to everyone who weighed in on the future of Cost Curve. With that feedback, I'm committed to making 2025 a banner year

American Health Care : The Best (?) System that $4.9 Trillion Can Buy

And PBM reform seems to be dead. For now. Maybe. (I'm choosing to think that reform is merely pining for the fjords)

A Section-by-Section Breakdown of the PBM Provisions in the Big Year-End Spending Bill

Plus Pfizer pulls back the curtain on what the IRA's Part D benefit design change will cost them next year: $1 billion

Today Is the Biggest Day Ever for PBM News, No?

And I have a survey on the future direction of Cost Curve for you all. I'd be eternally grateful for your feedback.

J&J Expands Its Legal Attack on 'Alternative Funding Programs' to Include a PBM

And 2024 has seen an explosion in great curation and commentary around health policy, and I'm grateful for that